Mediclinic International Plc

Public consensus   -   Last updated 23/07/21

Reporting currency: GBP
Reporting unit: Absolute
 
NO. OF
FORECASTS
FY22
CONSENSUS
23/07/21
FY22
MIN
FY22
MAX
Hirslanden (CHF'm) - Adjusted
Revenue
9
1,819
1,793
1,835
EBITDA
9
282
273
293
EBITDA margin (%)
9
15.5
15.0
16.0
Average FX rate GBP/CHF
9
1.26
1.19
1.41
Southern Africa (ZAR'm) - Adjusted
Revenue
9
17,250
16,884
18,347
EBITDA
9
3,217
2,994
3,555
EBITDA margin (%)
9
18.6
17.5
19.4
Average FX rate GBP/ZAR
9
20.25
19.19
21.30
Middle East (AED'm) - Adjusted
Revenue
9
3,951
3,910
3,997
EBITDA
9
580
550
604
EBITDA margin (%)
9
14.7
14.0
15.1
Average FX rate GBP/AED
9
5.09
4.80
5.40
Adjusted Group (GBP'm)
Revenue
9
3,068
2,968
3,124
EBITDA
9
494
479
503
EBITDA margin (%)
9
16.1
15.7
16.3
D&A
9
(217)
(230)
(198)
Operating profit
9
277
263
300
Net finance cost
9
(70)
(92)
(50)
Share of profit of equity accounted investment
7
0
(10)
6
Earnings (equity holders)
9
147
134
172
Earnings per share (pence)
9
19.8
18.2
23.4
Dividend per share (pence)
9
3.1
-
6.1
Net Debt
9
1,833
1,045
2,178
Net cash generated from operating activities
8
370
313
467
Total Group Capex
9
220
200
238

Disclaimer

Mediclinic International plc (“Mediclinic”) does not endorse or adopt any of the consensus estimates expressed in this report. The report represents the views of analysts from which the consensus estimates are derived. Mediclinic will not provide any commentary on the consensus or answer questions on it. The circulation of the consensus by Mediclinic is not mandatory and Mediclinic may amend its practice on this at any time.